This study investigated the effects of berberine, a natural alkaloid, on doxorubicin-induced cardiotoxicity in mice. Mice were injected intraperitoneally with saline 10 ml/kg (n = 10), doxorubicin 2.5 mg/kg (n = 10), 60 mg/kg berberine 1 h before doxorubicin 2.5 mg/kg (n = 10), or 60 mg/kg berberine alone (n = 10) every other day for 14 days. Body weight, general condition and mortality were recorded over the 14-day study period. Electrocardiography was performed before the start of treatment and after 14 days and plasma lactate dehydrogenase (LDH) activity was measured after 14 days. At the end of the study period the heart was excised and examined histologically. An increase in mortality, an initial decrease in body weight, increased LDH activity, prolongation of QRS duration and increased myocardial injury were seen in the doxorubicin-treated group compared with the saline control group. These changes were significantly attenuated by pretreatment with berberine. The study suggests that berberine may have a potential protective role against doxorubicin-induced cardiotoxicity in mice.
Berberine Attenuates Doxorubicininduced Cardiotoxicity in Mice Introduction
Doxorubicin is a potent chemotherapeutic drug that is used extensively for the treatment of haematological malignancies and solid tumours. 1 The clinical usefulness of doxorubicin has been limited largely by the risk of cardiomyopathy and life-threatening heart failure, 2,3 which precludes some patients from receiving a highly effective treatment. Development of cardiotoxic sideeffects is associated with a poor prognosis. 4 The use of cardioprotective agents together with doxorubicin is a possible therapeutic approach. Several pharmacological agents have been shown to reduce the cardiotoxicity of doxorubicin, including antioxidants, ironchelating agents and haematopoietic cytokines. 5 -7 Very few, if any, agents have been proven to be applicable in clinical practice and the search for a cardioprotective drug to suppress doxorubicin-induced complications is ongoing.
Berberine, an isoquinoline alkaloid originally isolated from the Chinese herb Coptis chinensis (Huanglian), has been shown to display a wide array of pharmacological activities which include antimicrobial, antidiarrhoeal, antidiabetic, antihyper lipidaemic, anti-inflammatory and antiproliferative effects. 8 studies have shown that berberine is beneficial in combating cardiovascular disease. 9 The present study investigated the possible protective effects of berberine in doxorubicin-induced cardiotoxicity in mice.
Materials and methods

ANIMALS
BALB/c mice of either gender, 4 -6 weeks old, with a body weight of 20 -25 g (Animal Centre, Chongqing University of Medicine, Chongqing, China) were used in the study. The animals were acclimatized to laboratory conditions for 1 week and were kept in a 12h light/12-h dark cycle with free access to food and water.
All animal procedures were approved by the Ethical Committee for Animal Experiments, Southwest University, Chongqing, China.
EXPERIMENTAL PROTOCOL
The mice were randomly divided, according to a table of random numbers, into four groups. They were injected intraperitoneally on alternate days for a total of seven doses (14 days total period) with the following: control group, injected with saline 10 ml/kg; doxorubicin group, injected with doxorubicin 2.5 mg/kg (Sigma-Aldrich, St Louis, MO, USA); berberine plus doxorubicin group, injected with berberine 60 mg/kg 1 h before injection with doxorubicin 2.5 mg/kg; and berberine alone group, injected with berberine 60 mg/kg. All analyses were performed at the end of 14 days. The berberine was a gift kindly provided by Dr Xue-Gang Li (School of Pharmaceutical Sciences, Southwest University, Chongqing, China).
ASSESSMENT OF SURVIVAL AND BODY WEIGHT
The general condition, body weight and mortality of the mice were recorded daily throughout the 14-day study period.
ECG RECORDING
An electrocardiogram (ECG) was performed before the start of drug treatment and on conscious animals at the end of the 14-day study period (MedLab-TA6016 ECG recorder; Nanjing MedEase Science and Technology Co. Ltd, Nanjing, China). Needle electrodes were inserted subcutaneously into the four limbs and at the correct positions on the chest and connected to the ECG recorder. The QRS duration was measured; this has previously been reported as the most reliable ECG parameter for evaluation of doxorubicin-induced cardiotoxicity. 10
MEASUREMENT OF LDH ACTIVITY
Blood samples were collected at the end of the experiment (i.e. after 14 days) from the inner canthus using a capillary tube under chloral hydrate anaesthesia. The samples were stored on ice before being centrifuged at 3053 g for 5 min within 1 h of collection. Plasma lactate dehydrogenase (LDH) activity was determined using a commercially available kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions.
HISTOLOGICAL EXAMINATION
At the end of the study period, after the ECG recording had been taken, all mice were killed and the hearts were excised, weighed and fixed in 4% formaldehyde. Tissue sections (5 µm) were stained with haematoxylin and eosin and histological examination was conducted using a light microscope.
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® statistical package, version 10.0 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Results were compared using one-way analysis of variance and the Student's t-test. A two-tailed P-value < 0.05 was considered to X Zhao, J Zhang, N Tong et al. Berberine attenuates doxorubicin-induced cardiotoxicity be statistically significant.
Results
A total of 40 BALB/c mice were included in the study and equally divided between the four groups: controls (n = 10), doxorubicin (n = 10), berberine plus doxorubicin (n = 10) and berberine alone (n = 10).
During the 14-day treatment period, doxorubicin-treated mice showed reduced activity, decreased appetite and progressive physical exhaustion compared with the other three groups. Mice treated with doxorubicin alone showed initial weight loss followed by weight gain after day 6, whereas mice treated with saline, berberine alone or berberine plus doxorubicin did not experience weight loss, instead showing steady weight gain throughout the study period ( Fig. 1 ). Although the final body weight was increased compared with baseline in all four groups, the final body weight in doxorubicintreated mice was lower than in the control group. The growth-retarding effect of doxorubicin was ameliorated in mice pretreated with berberine. Mortality rates in the control, doxorubicin, berberine, or berberine plus doxorubicin groups were 0%, 50%, 0% and 20%, respectively.
Examples of ECG records from mice in each of the four groups at the end of the 14-day study period are given in Fig. 2A -2D . Doxorubicin-treated mice showed significant prolongation of QRS duration after the 14-day Fig. 2E ). After pretreatment with berberine, this prolonging of the QRS complex was significantly attenuated compared with mice receiving doxorubicin alone (P < 0.05) ( Fig. 2E ). No abnormal ECG Representative examples of the histological appearance in the control, doxorubicintreated and berberine plus doxorubicintreated groups after the 14-day treatment period are given in Fig. 3 . Structural abnormalities were not found in the berberine group (not shown) or control group (Fig. 3A) . Cardiac tissues from doxorubicin-treated animals showed widespread marked structural abnormalities, including cardiomyocyte necrosis, vacuolization, myofibrillar loss and infiltration of mononuclear cells (Fig. 3B) . In contrast, necrotic cardiomyocytes, vacuolization and myofibrillar loss were rare in tissue from mice receiving berberine pretreatment followed by doxorubicin ( Fig. 3C ).
Serum LDH activity in the four groups after the 14-day treatment period is shown in Fig. 4 . In doxorubicin-treated mice, LDH activity was significantly higher (5619.1 U/g protein) than in controls (3863.5 U/g protein) (P < 0.05). When the mice were pretreated with berberine, LDH activity was significantly decreased, compared with the doxorubicin group, to 4266.7 U/g protein (P < 0.05).
Discussion
The present study showed that berberine pretreatment produced dramatic suppression of the cardiotoxicity associated with doxorubicin administration. Pretreatment with the alkaloid berberine attenuated the doxorubicin-induced reduction in body weight, reduced prolongation of QRS duration, reduced myocardial injury and reduced LDH activity. This suggests that berberine may have a protective role in doxorubicin-induced cardiotoxicity and may be a potential agent for attenuation and prevention of the serious cardiac complications of doxorubicin in clinical practice.
Doxorubicin has been reported to be a very potent and effective anticancer agent. 11 The therapeutic application of doxorubicin has, however, been greatly limited by its dose-dependent toxicity, especially severe cardiotoxicity. 12, 13 Cardiotoxic effects include hypotension, arrhythmia, cardiac dilation and ventricular failure. 14 The prolongation of QRS duration and myocardial injury seen in the present study were consistent with these reported effects of doxorubicin therapy.
Berberine, originally isolated from the Chinese herb Coptis chinensis (Huanglian), possesses antimicrobial, antidiabetic and 15, 16 In addition, experimental and clinical evidence suggest that it is beneficial in combating atherosclerotic and cardiovascular disease. 9, 17, 18 A decrease in body weight, debilitation and death were associated with administration of doxorubicin in the present study. The 2.5 mg/kg cumulative dose of doxorubicin produced systemic adverse effects: 50% of the mice died before the end of the study and mean body weight was below that of the control group for most of the study duration. It has been reported that the reduction in body weight associated with doxorubicin is the result of a direct toxic effect on the intestinal mucosa, 19 but that cardiomyopathy makes the most important contribution to the survival of experimental animals after long-term treatment with doxorubicin. 20 The present study highlighted these toxic effects of doxorubicin. The administration of seven doses of berberine 60 mg/kg over 14 days effectively prevented doxorubicin-induced body weight reduction and mortality in mice. Since the increased mortality of experimental animals treated with doxorubicin is linked to the induction of cardiomyopathy, it is likely that berberine reduces the mortality of doxorubicin-treated mice through the attenuation of doxorubicin-induced cardiotoxicity. Berberine also attenuated weight loss, which could be the result of a direct toxic effect of doxorubicin on the intestinal mucosa. Thus, it is possible that berberine reduced mortality by attenuating the effect of doxorubicin on the intestinal mucosa as well as affecting its cardiotoxicity. Further studies are needed to test this hypothesis.
It has been reported that the severity of ECG alterations, including the prolongation of QRS duration, Q-T prolongation and Twave flattening, parallels doxorubicininduced cardiotoxicity in patients. 21 In agreement with a previous clinical trial, 22 QRS prolongation was demonstrated in doxorubicin-treated mice in the present study and was significantly increased compared with control mice. The QRS prolongation induced by doxorubicin, however, was attenuated by pretreatment with berberine.
Histological changes in cardiac tissue, including cardiomyocyte necrosis, vacuolization, myofibrillar loss and infiltration of mononuclear cells, were seen in the present study in doxorubicin-treated mice, together with increased serum LDH activity, a marker of myocardial damage seen in conditions such as myocardial infarction, renal infarction and haemolysis. 23 Myocardial cell death and subsequent cardiac dysfunction are major problems in doxorubicin-induced cardiotoxicity. Cardiomyocytes are terminally differentiated cells and, although adult myocardium has been shown actively to synthesize DNA, the research suggests that myocardial regeneration is not sufficient to restore cardiac function. 24 Doxorubicininduced cardiomyopathy is, therefore, irreversible. The administration of seven doses of berberine 60 mg/kg over 14 days effectively ameliorated myocardial damage and LDH release in doxorubicin-treated mice, suggesting that berberine has the potential to protect against cardiotoxicity in doxorubicinexposed patients.
There were a number of limitations to the present study. First, the molecular mechanisms involved in doxorubicininduced cardiotoxicity in mice or in the cardioprotective effects of berberine were not investigated. Several mechanisms have been proposed to account for doxorubicin-induced cardiotoxic side-effects, including free radical formation, Ca 2+ overload and the involvement of prostaglandins, thromboxanes and leucotrienes. 25 Further studies are needed to explain how berberine ameliorates the cardiotoxicity associated with doxorubicin. Secondly, the present study investigated the effect of a single dose of berberine; the use of varying doses would have allowed the production of a dose-effect curve. Thirdly, the outcome of doxorubicin and berberine administration in mice may not reflect the overall effects of such treatment in patients.
In summary, the present study reported the protective effects of berberine against doxorubicin-induced cardiotoxicity in an in vivo mouse model. Pretreatment with berberine significantly inhibited doxorubicin-induced prolongation of QRS duration, attenuated myocardial injury and reduced LDH activity. This suggests that berberine may have a role in the attenuation and prevention of the serious cardiac complications of doxorubicin. The combination of berberine with doxorubicin is a novel strategy that has the potential for protecting against doxorubicin-induced cardiotoxicity in clinical practice.
